CorMedix Inc. to Report Second Quarter 2016 Financial Results

Conference Call to be held Friday, August 5, 2016, at 9:00 a.m. Eastern Time

BEDMINSTER, NJ / ACCESSWIRE / August 2, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that it will issue its financial results for the second quarter ended June 30, 2016 on Friday, August 5, 2016.

CorMedix CEO, Randy Milby will host a conference call on Friday, August 5, 2016, at 9:00 AM eastern time to discuss the financial results and recent corporate developments.

Dial-In (Toll Free): 877-407-9210
International Dial-In: 201-689-8049

Replay Number: 877-481-4010
Replay International: 919-882-2331
Conference ID: 10068

Teleconference Replay available until August 12, 2016, 11:59 PM

About CorMedix Inc.

CorMedix Inc. is an emerging commercial-stage biopharmaceutical company that initiated a Phase 3 clinical study of a novel anti-infective solution Neutrolin in hemodialysis patients in the United States in December 2015. The Company seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of infectious and inflammatory diseases. CorMedix’s first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. The FDA has granted Fast Track status to Neutrolin Catheter Lock Solution and also has designated Neutrolin as a Qualified Infectious Disease Product for oncology, hemodialysis, and critical care/intensive care patients, where catheter-related blood stream infections and clotting can be life-threatening. The initial and planned indications aim to address significant needs in catheter-based treatments in the U.S. and the rest of the world. For more information visit: www.cormedix.com.

For Investors & Media:

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.: jdrumm@tiberend.com; (212) 375-2664
Janine McCargo: jmccargo@tiberend.com; (646) 604-5150

SOURCE: CorMedix Inc.

ReleaseID: 443097